title: [Comparative safety evaluation of first- and second-line therapy with carboplatin + paclitaxel for advanced non-small cell lung cancer].
abstract: The study was carried out to compare the incidence of hematological toxicity between 14 cases with CDDP+VNR as first line therapy followed by CBDCA+PTX as second-line therapy, and 21 cases with CBDCA+PTX as first-line therapy for nonsmall cell lung cancer. The incidences of thrombocytopenia were 78. 6% in the second-line and 42. 9% in the first-line with a significant difference (p=0. 0364). The incidences of neutropenia at grade 3 or more in the second-line and the first-line were 71. 4% and 52. 4%, respectively, with a tendency to be higher in the second-line. When creatinine values increased by 25%or more, even though they were within normal limits, following the CDDP+VNR in the first-line, the occurrence of neutropenia at grade 3 or more was significant (p=0. 016) in the first-course of the second-line therapy comprising CBDCA+PTX. The present findings suggest that when CBDCA+PTX therapy is performed following CDDP+VNR therapy, renal functions must be observed carefully, including changes in creatinine, during the CDDP+VNR therapy. When doses are determined for CBDCA+PTX as second-line therapy, dose reduction may be one of methods used to avoid serious hematological toxicity.
authors.affiliation: Department of Pharmacy, Gifu Prefectural Tajimi Hospital, Japan.
authors.forename: Kazuyo
authors.initials: K
authors.lastname: Morihata
authors.forename: Michio
authors.initials: M
authors.lastname: Kimura
authors.forename: Kazutomo
authors.initials: K
authors.lastname: Okada
authors.forename: Eiseki
authors.initials: E
authors.lastname: Usami
authors.forename: Toshiya
authors.initials: T
authors.lastname: Nakao
authors.forename: Tomoaki
authors.initials: T
authors.lastname: Yoshimura
authors.forename: Kunio
authors.initials: K
authors.lastname: Hayase
authors.forename: Tadashi
authors.initials: T
authors.lastname: Yasuda
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage; D013921:Thrombocytopenia / Q000139:chemically induced
chemical_list: D000970:Antineoplastic Agents; D000972:Antineoplastic Agents, Phytogenic; D016190:Carboplatin; D017239:Paclitaxel